Steven Holtzman joined Decibel Therapeutics as president and chief executive officer in 2016. Decibel discovers and develops novel therapeutic approaches to treat hearing loss and other hearing disorders.
Prior to Decibel, Holtzman served as executive vice president of corporate development at Biogen, Inc. At Biogen, he created and led the program leadership and management group through six new drug approvals. He also led the business development and M&A group through successful completion of numerous transactions.
Prior to Biogen, Holtzman served as the founder, chief executive officer, and chair of the board of directors of Infinity Pharmaceuticals, Inc., a cancer drug discovery and development company. He was also an early leader and the chief business officer of Millennium Pharmaceuticals (now Takeda Oncology), a pioneer in largescale genetics and genomics, and was a founder, member of the board, and the executive vice president of DNX Corporation, the first transgenic animal company. Holtzman is a member of the boards of directors of PMV Pharma, Visterra, Humatics, the Sync Project, and Molecular Partners. In the nonprofit arena, he is currently a trustee of Berklee College of Music and previously served as the vice chairman of the board of trustees of the Hastings Center for Ethics and the Life Sciences. From 1996 to 2001, he served as a presidential appointee to the U.S. National Bioethics Advisory Commission.
Holtzman graduated from Michigan State University, where he earned his bachelor of arts degree in philosophy, and his bachelor of philosophy graduate degree from Corpus Christi College, Oxford University, which he attended as a Rhodes Scholar.